bitopertin
Sign in to saveBitopertin (developmental code names RG1678; RO-4917838) is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results. As of 2024, it is under development for the management of erythropoietic protoporphyria (EPP).
Wikidata facts
- Mass
- 543.106275
Show 4 more facts
- Commons category
- Bitopertin
- chemical formula
- C₂₁H₂₀F₇N₃O₄S
- isomeric SMILES
- FC1=CC(=CN=C1N2CCN(CC2)C(=O)C3=CC(=CC=C3O[C@H](C(F)(F)F)C)S(=O)(=O)C)C(F)(F)F
- canonical SMILES
- FC1=CC(=CN=C1N2CCN(CC2)C(=O)C3=CC(=CC=C3OC(C(F)(F)F)C)S(=O)(=O)C)C(F)(F)F
Sources (2)
via Wikidata · CC0
~3 min read
Article
4 sectionsContents
- Erythropoietic protoporphyria
- Schizophrenia
- See also
- References
{{Drugbox | IUPAC_name = {4-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}{5-(methylsulfonyl)-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl}methanone | image = Bitopertin.svg | image_class = skin-invert-image | width = 270
| IUPHAR_ligand = 7546 | CAS_number = 845614-11-1 | ChemSpiderID = 25034798 | PubChem = 24946690 | ATC_prefix = none | ChEMBL = 1169880 | UNII = Q8L6AN59YY | KEGG = D10186